As TSC is a multi-system disorder that affects the brain, kidneys and other organs, depending on TSC disease manifestations and toxicity profile, it may ultimately be advantageous to have mTOR inhibitors with differing tissue distribution profiles. The gene discussed is MTOR; the disease is tuberous sclerosis.